For example, vanucizumab, a bsAb targeting VEGF-A and angiopoietin-2, demonstrated acceptable tolerability and decreased tumor vascularity in a heterogeneous population of patients with solid tumors (13/42 had CRC) [31]. This evidence concerns the gene VEGFA and colorectal carcinoma.